Transgene SA
PAR:TNG
Intrinsic Value
Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. [ Read More ]
The intrinsic value of one TNG stock under the Base Case scenario is 4.41 EUR. Compared to the current market price of 1.22 EUR, Transgene SA is Undervalued by 72%.
Valuation Backtest
Transgene SA
Run backtest to discover the historical profit from buying and selling TNG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Transgene SA
Current Assets | 18m |
Cash & Short-Term Investments | 15.7m |
Receivables | 778k |
Other Current Assets | 1.5m |
Non-Current Assets | 27.2m |
Long-Term Investments | 1.3m |
PP&E | 12.3m |
Intangibles | 80k |
Other Non-Current Assets | 13.5m |
Current Liabilities | 10m |
Accounts Payable | 4.5m |
Other Current Liabilities | 5.5m |
Non-Current Liabilities | 19.6m |
Long-Term Debt | 16m |
Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
Transgene SA
Revenue
|
7.6m
EUR
|
Operating Expenses
|
-37.7m
EUR
|
Operating Income
|
-30m
EUR
|
Other Expenses
|
7.7m
EUR
|
Net Income
|
-22.3m
EUR
|
Free Cash Flow Analysis
Transgene SA
TNG Profitability Score
Profitability Due Diligence
Transgene SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Transgene SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
TNG Solvency Score
Solvency Due Diligence
Transgene SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Transgene SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TNG Price Targets Summary
Transgene SA
According to Wall Street analysts, the average 1-year price target for TNG is 4.54 EUR with a low forecast of 3.54 EUR and a high forecast of 5.67 EUR.
Shareholder Return
TNG Price
Transgene SA
Average Annual Return | -6.51% |
Standard Deviation of Annual Returns | 43.9% |
Max Drawdown | -73% |
Market Capitalization | 122.7m EUR |
Shares Outstanding | 100 566 564 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Contact
IPO
Employees
Officers
The intrinsic value of one TNG stock under the Base Case scenario is 4.41 EUR.
Compared to the current market price of 1.22 EUR, Transgene SA is Undervalued by 72%.